

LIST OF TABLES

Table		Page
2.01	Estimated prevalence of anemia in different age/sex groups in the world	15
2.02	Factors associated with the etiology of anemia in pregnancy	17
2.03	Changes in blood volume in pregnancy	29
2.04	Iron cost of pregnancy	30
2.05	Daily iron requirements for correction of anemia and provision of pregnancy needs	33
2.06	Maternal deaths attributable to anemia	34
2.07	Pregnancy outcome in relation to mean Hb levels	36
2.08	Side effects with different levels of iron therapy in pregnant women	44
2.09	Effect of different dose levels of iron on changes in prevalence of anemia : a summary of randomized trials in pregnant women	48
2.10	Effect of different dose levels of iron on Hb levels : A summary of randomized trials in pregnant women	50
2.11	Range of Hb rise with different levels of iron supplementation - a compilation from published studies	54
2.12	Hemoglobin response in relation to duration of iron therapy - a compilation from published studies	57
2.13	Effect of iron supplementation with and without folic acid on rise in Hb during pregnancy	58
2.14	Effect of different dose levels of iron on serum ferritin, serum iron and transferrin saturation in pregnant women	62

List of Tables

Table		Page
3.01	Parameters measured prior to delivery	101
3.02	Parameters measured postnatally	101
3.03	Validation of morbidity recall	111
4.01	Areas and number of subjects selected for the study	122
4.02	Number and percent of pregnant women who were available for follow up	123
4.03	Reasons for drop-out of the study in the three iron treatment groups	124
4.04	Socio-economic characteristics of the subjects in the three iron treatment groups	127
4.05	Obstetric history of the subjects in the three iron treatment groups	132
4.06	Utilization of health care services of the subjects in the three iron treatment groups	134
4.07	Gestational age, anthropometry and hemoglobin of the subjects in the three iron treatment groups	137
4.08	Reasons for low compliance (< 30 tablets/month) in the three iron treatment groups	154
4.09	Percent subjects who marked the calendar at each contact	157
4.10	Compliance as number of tablets consumed : Autoseal pack vs Calendar (for only those who marked the calendar)	159
4.11	Compliance as mean tablet consumption : Autoseal pack vs calendar (for only those who marked the calendar)	160
4.12	Correlation between compliance measured by counting leftover tablets vs calendar marking	161

List of Tables

Table		Page
4.13	Reasons for non-use of the calendar at each contact	163
4.14	Nature of side effects reported by the subjects in the three iron treatment groups at different gestational periods	166
4.15	Mean tablet consumption and mean Hb of the subjects who reported/did not report any side effect during supplementation	168
4.16	Nature of beneficial effects reported by the subjects in the three iron treatment groups	173
4.17	Results of chi-square analysis for the frequency of beneficial effects reported in the three iron treatment groups at different contacts	175
4.18	Mean tablet consumption, mean iron intake and mean folic acid intake in the three iron treatment groups (OL and NOL)	179
4.19	Percent prevalence of anemia before and after iron therapy in the three iron treatment groups (OL)	182
4.20	Rise in Hb of the subjects in the three iron treatment groups (OL) (mean \pm SE)	185
4.21	Regression coefficients and adjusted means of final Hb in the three iron treatment groups (OL)	187
4.22	Rise in Hb of the subjects in the three iron treatment groups (NOL) (mean \pm SE)	187
4.23	Rise in Hb in relation to duration of supplementation in the three iron treatment groups (mean \pm SE)	192
4.24	Mean rise in Hb at different levels of tablet consumption in the three iron treatment groups	194
4.25	Morbidity profile of the subjects at different gestational periods in the three iron treatment groups - Infectious morbidities	197

List of Tables

Table		Page
4.26	Percent subjects experiencing two or more infectious morbidities, at different gestational periods in the three iron treatment groups	199
4.27	Mean episodes and mean days of infectious morbidities experienced at different gestational periods in the three iron treatment groups	200
4.28	Final Hb of the subjects reporting and not reporting infectious morbidities in the three iron treatment groups (mean \pm SE)	203
4.29	Percent subjects experiencing two or more anemia or work related morbidities at different gestational periods in the three iron treatment groups	205
4.30	Other morbidities in the subjects at different gestational periods in the three iron treatment groups	207
4.31	Weight gain of the subjects in the three iron treatment groups - (OL) (mean \pm SE)	208
4.32	Weight gain of the subjects in the three iron treatment groups - (NOL) (mean \pm SE)	209
4.33	Weight gain (mean \pm SE) of the subjects who reported improved appetite due to iron supplementation in the three treatment groups	215
4.34	Mean gestational duration and percent premature deliveries in the three iron treatment groups	218
4.35	Regression analysis of factors affecting gestational duration	221
4.36	Birthweight (mean \pm SE) and percent low birthweight in the three iron treatment groups (OL and NOL)	223
4.37	Birthweight (mean \pm SE) and percent low birth weight of full term infants (\geq 36 w) in the three iron treatment groups	227
4.38	Regression analysis of factors affecting birthweight	227

List of Tables

Table		Page
4.39	Weight and Hb of the subjects at 6 months postpartum in the three iron treatment groups (mean \pm SE)	231
4.40	Prevalence of anemia at 6 months postpartum in the three iron treatment groups	233
4.41	Feeding practices of the infants at 3rd month and 6th month in the three iron treatment groups	237
4.42	Height of the infants in the three iron treatment groups at 3 months and 6 months of age (mean \pm SE)	239
4.43	Weight of the infants in the three iron treatment groups at 3 months and 6 months of age (mean \pm SE)	242
4.44	Mean hemoglobin and prevalence of anemia in infants at 6 months in the three iron treatment groups (mean \pm SE and %)	246
4.45	Morbidity profile of the infants in the three iron treatment groups	249
5.01	Summary Highlights of the Study : Responses to iron supplementation at three dose levels	259